Injectable bone morphogenetic protein

1. A method of treating a bone defect, the method comprising administering to the bone defect an injectable solution comprising 28 μg of bone morphogenetic protein-2 (BMP-2) in an aqueous carrier, wherein the injectable solution has a pH of about 6.0, and wherein the injectable solution is administered as a single dose injection to the bone defect.

2. The method of claim 1 , wherein the BMP-2 is recombinant human BMP-2 (rhBMP-2).

3. The method of claim 1 , wherein the aqueous carrier comprises saline, dextrose, sterile water for injection, phosphate buffered saline, blood, or a combination thereof.

4. The method of claim 1 , wherein the injectable solution further comprises a buffering agent comprising tris(hydroxymethyl)aminomethane (Tris), ethylenediaminetetraacetic acid (EDTA), 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), sodium acetate, sodium citrate, sodium phosphate, potassium phosphate, phosphate buffered saline (PBS), sodium chloride, potassium chloride, calcium chloride, glycerol, sucrose, glycine, L-glutamic acid, polysorbate 80 or a combination thereof.

5. The method of claim 4 , wherein the buffering agent comprises sucrose, glycine, L-glutamic acid, sodium chloride, polysorbate 80 or a combination thereof.

6. The method of claim 4 , wherein the buffering agent in the injectable solution is at a concentration from about 1 mM to 100 mM.

7. The method of claim 1 , wherein the injectable solution further comprises a clotting factor in an amount of about 0.0001% to about 5% of the injectable solution.

8. The method of claim 1 , wherein (i) the injectable solution is administered percutaneously to a long bone fracture; or (ii) the injectable solution is injected directly into a fracture site that has a hematoma.

9. The method of claim 1 , wherein the aqueous carrier is not osteoinductive or osteoconductive.